
The financing provides working capital, and facilitates advances toward regulatory approval and preparation for commercialization of Pacira’s EXPAREL™ program.
EXPAREL™ is the company’s bupivacaine-based product administrated by wound infiltration that is designed to deliver extended relief of postoperative pain.
FinSMEs
11/05/2010